Molecular background of α-fetoprotein in liver cancer cells as revealed by global RNA expression analysis

Cancer Science

Volumn 99, Issue 12, 2008, Pages 2402-2409

  Saito, Shigeru ^a   Ojima, Hidenori ^a   Ichikawa, Hitoshi ^a   Hirohashi, Setsuo ^a   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GLYPICAN 3; IRON; LIPID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; WNT PROTEIN;

ANIMAL CELL; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; DATA MINING; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRON METABOLISM; LIPID DEGRADATION; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 53349176261     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00973.x     Document Type: Article

References (52)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-85.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827-41.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
5. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-3.
6. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (Suppl 1): 57-63.
7. Arrigoni A, Andriulli A, Gindro T, Piantino P, Capussotti L, Rizzetto M. Pattern analysis of serum alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma in liver cirrhosis. Int J Biol Markers 1988; 3: 172-6.
8. Tangkijvanich P, Anukulkarnkusol N, Suwangool P et al. Clinical characteristics and prognosis of hepatocellular carcinoma: Analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-8.
9. Han K, Tzimas GN, Barkun JS et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39-45.
10. Marubashi S, Dono K, Sugita Y et al. Alpha-fetoprotein mRNA detection in peripheral blood for prediction of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2006; 38: 3640-2.
11. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007; 52: 776-82.
12. Carlini P, Ferranti P, Polizio F, Ciriolo MR, Rotilio G. Purification and characterization of alpha-fetoprotein from the human hepatoblastoma HepG2 cell line in serum-free medium. biometals 2007; 20: 869-78.
13. Dudich E, Semenkova L, Dudich I, Denesyuk A, Tatulov E, Korpela T. Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction. FEBS J 2006; 273: 3837-49.
14. Dudich E, Semenkova L, Dudich I et al. Alpha-fetoprotein causes apoptosis in tumor cells via a pathway independent of CD95, TNFR1 and TNFR2 through activation of caspase-3-like proteases. Eur J Biochem 1999; 266: 750-61.
15. Semenkova LN, Dudich EI, Dudich IV. Induction of apoptosis in human hepatoma cells by alpha-fetoprotein. Tumour Biol 1997; 18: 261-73.
16. Li MS, Li PF, Yang FY, Du GG, He SP, Li G. The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells. Cell Res 2002; 12: 151-6.
17. Li MS, Li PF, Li G, Du GG. Enhancement of proliferation of HeLa cells by the alpha-fetoprotein. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002; 34: 769-74.
18. Wang XW, Xu B. Stimulation of tumor-cell growth by alpha-fetoprotein. Int J Cancer 1998; 75: 596-9.
19. Wang XW, Xie H. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci 1999; 64: 17-23.
20. Dudich E, Semenkova L, Gorbatova E et al. Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumour Biol 1998; 19: 30-40.
21. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 2004; 40: 609-17.
22. Shi L, Reid LH, Jones WD et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006; 24: 1151-61.
23. Sokal RR, Rohlf FJ. Biometry: The Principles and Practice of Statistics in Biological Research, 3rd edn. New York: W.H. Freeman and Co., 1995.
24. Dijkstra EW. A note on two problems in connection with graphs. Numerishe Mathematik 1959; 1: 269-71.
25. Kataoka H, Bonnefin P, Vieyra D et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res 2003; 63: 5785-92.
26. Wei CL, Wu Q, Vega VB et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124: 207-19.
27. Caruso ML, Valentini AM. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: A clinicopathological correlation. Anticancer Res 1999; 19: 3853-6.
28. Edis C, Kahler C, Klotz W et al. A comparison between alpha-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma. Transplant Proc 1998; 30: 780-1.
29. Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology 2007; 46: 1541-7.
30. Libbrecht L, Severi T, Cassiman D et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006; 30: 1405-11.
31. Wang XY, Degos F, Dubois S et al. Glypican-3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006; 37: 1435-41.
32. Hishinuma M, Ohashi KI, Yamauchi N et al. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma. Histopathology 2006; 49: 479-86.
33. Song HH, Shi W, Xiang YY, Filmus J. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005; 280: 2116-25.
34. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65: 6245-54.
35. Midorikawa Y, Ishikawa S, Iwanari H et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003; 103: 455-65.
36. Capurro M, Wanless IR, Sherman M et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.
37. Yamauchi N, Watanabe A, Hishinuma M et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005; 18: 1591-8.
38. Treichel U, Meyer zum Buschenfelde KH, Stockert RJ, Poralla T, Gerken G. The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol 1994; 75: 3021-9.
39. Yang J, Bo XC, Ding XR et al. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication. J Viral Hepat 2006; 13: 158-65.
40. Shin JW, Min M, Larrieu-Lahargue F et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: A role for FGF signaling in lymphangiogenesis. Mol Biol Cell 2006; 17: 576-84.
41. Kalabay L, Jakab L, Prohaszka Z et al. Human fetuin/ alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol 2002; 14: 389-94.
42. Camenisch G, Pisabarro MT, Sherman D et al. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin αvβ3 and induces blood vessel formation in vivo. J Biol Chem 2002; 277: 17281-90.
43. Guan X, Juarez JC, Qi X et al. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost 2004; 92: 403-12.
44. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004; 40: 252-9.
45. Chao Y, Li CP, Chau GY et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355-62.
46. Koide N, Nishio A, Igarashi J, Kajikawa S, Adachi W, Amano J. Alpha-fetoprotein-producing gastric cancer: Histochemical analysis of cell proliferation, apoptosis, and angiogenesis. Am J Gastroenterol 1999; 94: 1658-63.
47. Takahashi Y, Ohta T, Mai M. Angiogenesis of AFP producing gastric carcinoma: Correlation with frequent liver metastasis and its inhibition by anti-AFP antibody. Oncol Rep 2004; 11: 809-13.
48. Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, Siziba K. Hepatocellular carcinoma caused by iron overload: A possible mechanism of direct hepatocarcinogenicity. Toxicology 2006; 219: 41-52.
49. Di Micco P, Amitrano M, Niglio A, Fontanella A. Molecular and clinical conditions associated with venous thromboembolism in oncological patients. Exp Oncol 2006; 28: 194-7.
50. Gibson JB, Sobin LH. International Histological Classification of Tumours. Geneva: World Health Organization, 1978.
51. Naiki T, Nagaki M, Shidoji Y et al. Analysis of gene expression profile induced by hepatocyte nuclear factor 4α in hepatoma cells using an oligonucleotide microarray. J Biol Chem 2002; 277: 14011-19.
52. Zhang C, Li Z, Cheng Y et al. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res 2007; 13: 944-52.